vs
Side-by-side financial comparison of InflaRx N.V. (IFRX) and ORGANIGRAM GLOBAL INC. (OGI). Click either name above to swap in a different company.
ORGANIGRAM GLOBAL INC. is the larger business by last-quarter revenue ($39.6K vs $25.7K, roughly 1.5× InflaRx N.V.).
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the development of novel anti-inflammatory therapies targeting the complement C5a pathway. Its pipeline addresses unmet medical needs for severe inflammatory diseases including autoimmune and rare inflammatory disorders, serving global patient populations.
Organigram Global Inc. is a leading Canadian producer of high-quality recreational and medical cannabis products. It offers a diverse portfolio of dried flower, edibles, vape products and pre-rolls, primarily serving the domestic Canadian market while expanding operations in select international markets including parts of Europe.
IFRX vs OGI — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2022
| Metric | | |
|---|---|---|
| Revenue | $25.7K | $39.6K |
| Net Profit | — | $-76.5K |
| Gross Margin | 98.6% | — |
| Operating Margin | — | -128.4% |
| Net Margin | — | -192.9% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $25.7K | — | ||
| Q2 25 | $42.6K | — | ||
| Q2 24 | $6.9K | — | ||
| Q2 22 | — | $39.6K |
| Q3 25 | — | — | ||
| Q2 25 | $-15.6M | — | ||
| Q2 24 | $-15.0M | — | ||
| Q2 22 | — | $-76.5K |
| Q3 25 | 98.6% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | -128.4% |
| Q3 25 | — | — | ||
| Q2 25 | -36559.8% | — | ||
| Q2 24 | -217803.1% | — | ||
| Q2 22 | — | -192.9% |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-33.1M | $-15.2K |
| Free Cash FlowOCF − Capex | — | $-19.9K |
| FCF MarginFCF / Revenue | — | -50.2% |
| Capex IntensityCapex / Revenue | — | 11.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-33.1M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | $-29.2M | — | ||
| Q2 22 | — | $-15.2K |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | $-19.9K |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | -50.2% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | 11.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IFRX
Segment breakdown not available.
OGI
| Unrealized gain on changes in fair value of biological assets (Note 7) | $20.1K | 51% |
| Other | $19.6K | 49% |
